Vizsgálati helyszín
New Mexico Cancer Care Alliance
Albuquerque, New Mexico 87102, Egyesült ÁllamokMég nincs intézményhez kötve
- 5futó vizsgálat
- 7lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 13 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis7 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Lezárult6 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Felfüggesztve1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Incyte Corporation2 vizsgálat
- Regeneron Pharmaceuticals2 vizsgálat
- Alliance Foundation Trials, LLC.1 vizsgálat
- Criterium, Inc.1 vizsgálat
- Epizyme, Inc.1 vizsgálat
- és még 6
Futó vizsgálatok
Fut, nem toboroz
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015· 2/3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767· 2/3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420· 2. fázis· Criterium, Inc.· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· 3. fázis· Epizyme, Inc.· Forrás
Fut, nem toboroz
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02947685· 3. fázis· Alliance Foundation Trials, LLC.· Forrás
Lezárt vizsgálatok
Lezárult
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771· 2. fázis· Incyte Corporation· Forrás
Leállították
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
NCT04093362· 3. fázis· Taiho Oncology, Inc.· Forrás
Lezárult
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT03778931· 3. fázis· Stemline Therapeutics, Inc.· Forrás
Lezárult
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
NCT03941093· 3. fázis· Kyntra Bio· Forrás
Lezárult
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
NCT03358472· 3. fázis· Incyte Corporation· Forrás
Lezárult
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
NCT03365882· 2. fázis· SWOG Cancer Research Network· Forrás
Lezárult
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03056755· 2. fázis· Novartis Pharmaceuticals· Forrás
Hibát jelzek